Companies & Sectors
Reliance Communications clarifies on its spectrum plan
Mumbai : Reliance Communications is still waiting to hear from the government on its application for spectrum sharing and trading in 20 circles and that a decision will be taken only after getting replies on all the areas, the company has clarified to stock exchanges.
 
As per a filing posed on the Web site of the Bombay Stock Exchange on Wednesday, the company said applications were again made to the Depertment of Telecom (DoT) after it had notified the norms for liberaisation of spectrum on November 5 last year, along with a fee of Rs.50,000 per area.
 
"As part of the ongoing correspondence, DoT has issued intimation/demand letters for 16 circles and is yet to decide for the remaining four. Once decided in totality, the company will have the option whether to pay the said amount and liberalise or not," the filing said.
 
"Thus this process is still ongoing and the matter has not yet achieved finality."
 
The letter to the exchanges also quoted the excerpts from chairman Anil Ambani's statement to the shareholders on September 30 in which he said Reliance Communications was the only operator in India to hold 5 MHz or more of the valuable 800-850 MHz band spectrum across the country.
 
"The company is at an advanced stage of discussions for finalising nationwide trading and sharing arrangements between Reliance Communications and Reliance Jio in the 800-850 MHz band, in line with the new policies of DoT," he had said.
 
The clarification was sought by the stock exchanges after some news reports that the government had asked Reliance Communications to pay Rs.5,384 crore to the exchequer before inking the pacts for spectrum sharing and trading.
 
"It may kindly be noted that liberalization, if any, will allow the spectrum to become technology agnostic and company can launch 4G or 5G services -- the spectrum can also be shared with any operator for 4G launch in same band," the filing said.
 
"Liberalization would also allow us an option to trade the spectrum with another operator having spectrum acquired through auction," it said, while also spelling out the timeline, based on which the norms were finally notified.
 
It said the government first came out with the liberalisation norms for 800 MHz on January 9 and it was only on September 24 that the guidelines for sharing were published. Then, on October 12, the norms for trading was approved. The actual guidelines were issued on November 5.
 
Nonetheless, the company said it has welcomed the guidelines.
 
"The announcement of trading and sharing policies by the government has now set the stage to extend our partnership to the next level of cooperation and will be a true game changer," the filing quoted Ambani as telling the shareholders.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.
 

 

User

Five Ad Trends to Red Flag in 2016
New fads, new ads to watch out for in the new year
 
There’s one thing we can all count on in 2016 and that is that new years bring new trends. Here’s five products and services to keep a watchful eye on to discern if the marketing claims are backed by real results. 
 
What’s in your genes?
DNA is hot. Whether you want to find out what ethnicity your ancestral lineage is or if you are a carrier of a disease or may develop one later in life, there is going to be no shortage of companies out there offering to help with direct-to-consumers testing services that likely require just a swipe of your cheek. But the FDA has sent warning letters to several genetic testing companies and at least one is facing class-action lawsuits alleging that it deceptively advertised that it can provide consumers with reports on more than 200 health conditions and traits. Then there are the companies that have run afoul of federal regulations by claiming that their products can work with your DNA to do everything from improve your skin to treating diseases. Expect more of the same this coming year. After all, it’s in the genes.
 
Brain drain
Will Smith’s new movie about football and concussions (called, you guessed it, “Concussion”) will keep the issue in the public spotlight and might spur even more products claiming to prevent this type of head trauma and treatments promising to spur speedy recoveries. In fact, concussion treatment clinics are popping up all over the nation, some with questionable staffing. Couple that with marketers playing to aging baby boomers seeking to stay sharp with dubious dietary supplements that promise to improve memory and what you’ve got is a no brainer about this trend being on the list for 2016.
 
Clean cars
The Paris climate change agreement to cut down on global emissions has every country thinking about clean energy. But with car companies such as Volkswagen copping to cheating on clean diesel emissions, and other car companies facing challenges to fuel efficiency claims, the drive to a sustainable planet will likely still be paved with potentially misleading claims.
 
Off-label prescriptions
The FDA’s crackdown on pharmaceutical companies promoting their drug products for off-label use hit a wall when a federal court judge in New York ruled that the First Amendment protects companies making truthful statements to promote drugs for alternative uses –meaning that drug companies will continue to aggressively find ways to “educate” doctors about the off-label use and put the drugs in the hands (and mouths) of patients. But a recent study published in JAMA found that consumers don’t always fare well when taking the drugs as treatments for illnesses or diseases they weren’t approved for by the FDA. The study found that the rate of side effects in off-label use — which constitutes 12 percent of all drug prescriptions — was 44 percent greater than when drugs were taken for their approved uses. More so, the study noted that 80% of off-label prescriptions weren’t supported by strong scientific evidence. All this may lead to more lawsuits but not much off-label use.
 
Ad or not?
Ad blocking is up and disguising ads is the counter attack. So, this coming year will bring increasing creative challenges to companies trying to stay one step ahead of consumers who are becoming savvier at not only blocking ads but spotting the ones that are supposed to blend into content. It’s not just that the ads can pop up in annoying places that are pushing consumers to block them, it’s the data tracking that is leaving consumers feeling vulnerable as ads follow them around in cyberspace. But companies are finding increasingly sophisticated ways to get their products in front of consumers’ view and respond to their reactions about the ads — Saatchi, for example, is testing billboards with hidden cameras that read viewers emotions and adapt the advertising accordingly. And regulators are trying to keep up. In December, the FTC issued a policy statement on rules that apply to digital advertising. In a nutshell the agency said that ads are deceptive if they convey or imply that they are something other than ads. Which brings us back to the question, can you spot the ad
 
 

User

When GST Comes…
Consumers will pay more for services and businessmen will face many...
Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Close

To continue


Please
Sign Up or Sign In
with

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)